Checkpoint Therapeutics Stock (NASDAQ:CKPT)


Chart

Previous Close

$3.30

52W Range

$1.36 - $3.97

50D Avg

$2.84

200D Avg

$2.22

Market Cap

$162.69M

Avg Vol (3M)

$669.08K

Beta

1.24

Div Yield

-

CKPT Company Profile


Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

23

IPO Date

Dec 19, 2016

Website

CKPT Performance


Peer Comparison


TickerCompany
ASMBAssembly Biosciences, Inc.
NLTXNeurogene Inc.
PIRSPieris Pharmaceuticals, Inc.
SPROSpero Therapeutics, Inc.
ALRNAileron Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
FBIOFortress Biotech, Inc.
CUECue Biopharma, Inc.
ATXIAvenue Therapeutics, Inc.
MBIOMustang Bio, Inc.
KODKodiak Sciences Inc.
LUMOLumos Pharma, Inc.
ACHLAchilles Therapeutics plc